Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial
RCT (n=140) found progression-free survival significantly longer in patients on fulvestrant who received capivasertib, a selective oral inhibitor of all 3 isoforms of serine/threonine kinase AKT, than in those who received placebo (10.3 v 4.8 months; HR 0.58; 95% CI 0.39–0.84).
Source:
The Lancet Oncology
SPS commentary:
A commentary notes two obvious questions that remain to be evaluated at this juncture are the possible first-line selection of capivasterib versus a CDK4/6 inhibitor and the ever-present question of drug sequencing. It adds that whether or not therapy-specific resistance patterns would confer an advantage of one drug over another upfront is unclear. It suggests that although the overall survival data for capivasertib are not yet mature, the magnitude of improvement in outcomes between agents might shift current treatment standards.